ArcelorMittal SA (ADR) news

   Watch this stock
Showing stories 1 - 1 of about 1   

Articles published

MT 10.72 -0.23 (-2.10%)
price chart
Elagolix Enters Phase 3
On June 5, 2012, Abbott Labs (NYSE:(ABT - Analyst Report) and Neurocrine Biosciences (NASDAQ: announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with ...